Overdosage was not observed in clinical trials with CAVERJECT (alprostadil injection) . If intracavernous overdose of CAVERJECT (alprostadil injection) occurs, the patient should be under medical supervision until any systemic effects have resolved and/or until penile detumescence has occurred. Symptomatic treatment of any systemic symptoms would be appropriate.
CAVERJECT (alprostadil injection) should not be used in patients who have a known hypersensitivity to the drug, in patients who have conditions that might predispose them to priapism, such as sickle cell anemia or trait, multiple myeloma, or leukemia, or in patients with anatomical deformation of the penis, such as angulation, cavernosal fibrosis, or Peyronie's disease. Patients with penile implants should not be treated with CAVERJECT (alprostadil injection) .
CAVERJECT (alprostadil injection) should not be used in women or children and is not for use in newborns.
CAVERJECT (alprostadil injection) should not be used in men for whom sexual activity is inadvisable or contraindicated.
Last reviewed on RxList: 3/3/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Caverject Information
Caverject - User Reviews
Caverject User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Sex & Relationships
Get tips to boost your love life.